tradingkey.logo

GeneDx Holdings Corp

WGS
查看詳細走勢圖
135.249USD
-0.841-0.62%
交易中 美東報價延遲15分鐘
3.91B總市值
1246.30本益比TTM

GeneDx Holdings Corp

135.249
-0.841-0.62%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.62%

5天

-0.79%

1月

-19.26%

6月

+52.08%

今年開始到現在

+75.97%

1年

+74.74%

查看詳細走勢圖

TradingKey GeneDx Holdings Corp股票評分

單位: USD 更新時間: 2025-12-24

操作建議

GeneDx Holdings Corp當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療服務供應商行業排名35/78位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價160.89。中期看,股價處於上升通道。近一個月,市場表現非常差,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

GeneDx Holdings Corp評分

相關信息

行業排名
35 / 78
全市場排名
159 / 4562
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 9 分析師
買入
評級
160.889
目標均價
+0.68%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

GeneDx Holdings Corp亮點

亮點風險
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
業績高增長
公司營業收入穩步增長,連續3年增長30.15%
估值高估
公司最新PE估值1254.05,處於3年歷史高位
機構減倉
最新機構持股32.52M股,環比減少2.75%
查克·羅伊斯持倉
明星投資者查克·羅伊斯持倉,最新持倉103.20K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.10

GeneDx Holdings Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

GeneDx Holdings Corp簡介

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
公司代碼WGS
公司GeneDx Holdings Corp
CEOStueland (Katherine A)
網址https://sema4.com/

常見問題

GeneDx Holdings Corp(WGS)的當前股價是多少?

GeneDx Holdings Corp(WGS)的當前股價是 135.249。

GeneDx Holdings Corp 的股票代碼是什麼?

GeneDx Holdings Corp的股票代碼是WGS。

GeneDx Holdings Corp股票的52週最高點是多少?

GeneDx Holdings Corp股票的52週最高點是170.870。

GeneDx Holdings Corp股票的52週最低點是多少?

GeneDx Holdings Corp股票的52週最低點是55.170。

GeneDx Holdings Corp的市值是多少?

GeneDx Holdings Corp的市值是3.91B。

GeneDx Holdings Corp的淨利潤是多少?

GeneDx Holdings Corp的淨利潤為-52.29M。

現在GeneDx Holdings Corp(WGS)的股票是買入、持有還是賣出?

根據分析師評級,GeneDx Holdings Corp(WGS)的總體評級為買入,目標價格為160.889。

GeneDx Holdings Corp(WGS)股票的每股收益(EPS TTM)是多少

GeneDx Holdings Corp(WGS)股票的每股收益(EPS TTM)是0.109。
KeyAI